<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956474</url>
  </required_header>
  <id_info>
    <org_study_id>CXL-04</org_study_id>
    <nct_id>NCT01956474</nct_id>
  </id_info>
  <brief_title>CXL-04 A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas</brief_title>
  <official_title>Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cxlusa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cxlusa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of ultraviolet-A (UVA)-induced
      cross-linking of corneal collagen (CXL) as a method to increase the biomechanical and
      biochemical stability of the cornea by inducing additional cross-links within or between
      collagen fibers using UVA light and the photo- mediator riboflavin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the results of Corneal Collagen Crosslinking (CXL) in patients with
      conditions that include Keratoconus, Pellucid Marginal degeneration, Post-LASIK ectasia, and
      patients with radial keratotomy who experience fluctuation in their vision. This is an
      outcomes study, all patients receive treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">February 3, 2017</completion_date>
  <primary_completion_date type="Actual">February 3, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Best Spectacle Corrected Visual Acuity (BSCVA)</measure>
    <time_frame>6-9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Uncorrected Visual Acuity (UCVA)</measure>
    <time_frame>6-9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Corneal topography</measure>
    <time_frame>6-9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Manifest Refraction</measure>
    <time_frame>6-9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Keratometry on topography and Pentacam</measure>
    <time_frame>6-9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Wavefront Refraction and aberrations</measure>
    <time_frame>6-9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1324</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Theralight crosslinking and Riboflavin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using UVA light and the photo- mediator riboflavin</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Theralight crosslinking and Riboflavin</intervention_name>
    <description>Corneal Collagen cross linking with UV light and riboflavin</description>
    <arm_group_label>Theralight crosslinking and Riboflavin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 8 years of age or older

          2. Having at least one of the following conditions:

               -  Keratoconus

               -  Post-LASIK ectasia

               -  Pellucid marginal degeneration

               -  Forme fruste pellucid marginal degeneration

               -  FFKC

               -  History of Radial Keratotomy with fluctuating vision.

               -  Terrien's Marginal Degeneration

          3. Signed written informed consent and/or assent

          4. Likely to complete all study visits

          5. Minimum corneal thickness of at least 250 microns measured by ultrasound or Pentacam
             for all indications other than Terrien's. For Terrien's, the minimal corneal thickness
             should be consistent with the surgeon's best surgical judgment.

        Exclusion Criteria:

          1. Severe corneal scarring that markedly affects vision

          2. Contraindications to any study medications or their components

          3. Pregnancy or breast feeding

          4. Active Herpes Corneal Disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Trattler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cxlusa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Excellence in Eye Care</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stulting Research Center at Woolfson Eye Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TLC Laser Eye Center</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Talamo Hatch Laser Eye Consultants, LLC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Eye Clinic</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TLC Laser Eye Center</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 27, 2013</study_first_submitted>
  <study_first_submitted_qc>October 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>keratoconus</keyword>
  <keyword>cross-linking</keyword>
  <keyword>Post-LASIK ectasia</keyword>
  <keyword>Pellucid marginal degeneration</keyword>
  <keyword>Forme fruste pellucid marginal degeneration</keyword>
  <keyword>FFKC</keyword>
  <keyword>Radial Keratotomy</keyword>
  <keyword>Terrien's Marginal Degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

